142 related articles for article (PubMed ID: 37972873)
1. Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study.
Zhan H; Fineberg S; Podany P; Zeng J; Wang Y; Harigopal M; Singh K
Hum Pathol; 2023 Dec; 142():15-19. PubMed ID: 37972873
[TBL] [Abstract][Full Text] [Related]
2. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
Kim HJ; Noh WC; Lee ES; Jung YS; Kim LS; Han W; Nam SJ; Gong G-; Kim HJ; Ahn SH
Breast Cancer Res; 2020 May; 22(1):54. PubMed ID: 32460816
[TBL] [Abstract][Full Text] [Related]
4. Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.
Yu KD; Wu SY; Liu GY; Wu J; Di GH; Hu Z; Hou YF; Chen CM; Fan L; Tang LC; Shen ZZ; Wu KJ; Zhuang ZG; Zhang HW; Shao ZM
Cancer; 2019 Jul; 125(13):2185-2193. PubMed ID: 30892700
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
[TBL] [Abstract][Full Text] [Related]
7. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
Bilici A; Olmez OF; Kaplan MA; Oksuzoglu B; Sezer A; Karadurmus N; Cubukcu E; Sendur MAN; Aksoy S; Erdem D; Basaran G; Cakar B; Shbair ATM; Arslan C; Sumbul AT; Sezgin Goksu S; Karadag I; Cicin I; Gumus M; Selcukbiricik F; Harputluoglu H; Demirci U
Acta Oncol; 2023 Apr; 62(4):381-390. PubMed ID: 37083566
[TBL] [Abstract][Full Text] [Related]
8. Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer.
Sella T; Gelber SI; Poorvu PD; Kim HJ; Dominici L; Guzman-Arocho YD; Collins L; Ruddy KJ; Tamimi RM; Peppercorn JM; Schapira L; Borges VF; Come SE; Warner E; Snow C; Jakubowski DM; Russell CA; Winer EP; Rosenberg SM; Partridge AH
Breast Cancer Res Treat; 2021 Feb; 186(1):157-165. PubMed ID: 33150547
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
10. Locoregional and Overall Recurrence After Neaodjuvant Endocrine Therapy Versus Chemotherapy in Postmenopausal Women With Estrogen Receptor+ HER2- Breast Cancer.
Wright JL; Saigal K; Reis IM; Zhao W; Takita C; Ambros T; Saeed AM; Sujoy V; Hurley J
Am J Clin Oncol; 2017 Oct; 40(5):490-497. PubMed ID: 26017482
[TBL] [Abstract][Full Text] [Related]
11. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
Palmieri C; Macpherson IR; Yan K; Ades F; Riddle P; Ahmed R; Owadally W; Stanley B; Shah D; Gojis O; Januszewski A; Lewanski C; Asher R; Lythgoe D; de Azambuja E; Beresford M; Howell SJ
Oncotarget; 2016 Mar; 7(11):13209-20. PubMed ID: 26334099
[TBL] [Abstract][Full Text] [Related]
13. Triple-Positive Breast Carcinoma: Histopathologic Features and Response to Neoadjuvant Chemotherapy.
Zeng J; Edelweiss M; Ross DS; Xu B; Moo TA; Brogi E; D'Alfonso TM
Arch Pathol Lab Med; 2021 Jun; 145(6):728-735. PubMed ID: 33112958
[TBL] [Abstract][Full Text] [Related]
14. Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population.
Hammond JB; Scott DW; Kosiorek HE; Parnall TH; Gray RJ; Ernst BJ; Northfelt DW; McCullough AE; Ocal IT; Pockaj BA; Cronin PA
Clin Breast Cancer; 2022 Feb; 22(2):186-190. PubMed ID: 34462208
[TBL] [Abstract][Full Text] [Related]
15. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Peintinger F; Buzdar AU; Kuerer HM; Mejia JA; Hatzis C; Gonzalez-Angulo AM; Pusztai L; Esteva FJ; Dawood SS; Green MC; Hortobagyi GN; Symmans WF
Ann Oncol; 2008 Dec; 19(12):2020-5. PubMed ID: 18667396
[TBL] [Abstract][Full Text] [Related]
16. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
[TBL] [Abstract][Full Text] [Related]
17. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
[TBL] [Abstract][Full Text] [Related]
18. Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors.
Wang S; Zhang Y; Yang X; Fan L; Qi X; Chen Q; Jiang J
World J Surg Oncol; 2013 Jul; 11(1):166. PubMed ID: 23883300
[TBL] [Abstract][Full Text] [Related]
19. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
